250 related articles for article (PubMed ID: 17000754)
21. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Nichols KE; Heath JA; Friedman D; Biegel JA; Ganguly A; Mauch P; Diller L
J Clin Oncol; 2003 Dec; 21(24):4505-9. PubMed ID: 14673037
[TBL] [Abstract][Full Text] [Related]
22. Highlight: BRCA1 and BRCA2 proteins in breast cancer.
Daniel DC
Microsc Res Tech; 2002 Oct; 59(1):68-83. PubMed ID: 12242698
[TBL] [Abstract][Full Text] [Related]
23. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
24. Lessons learned from BRCA1 and BRCA2.
Zheng L; Li S; Boyer TG; Lee WH
Oncogene; 2000 Dec; 19(53):6159-75. PubMed ID: 11156530
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
Koivusalo R; Krausz E; Helenius H; Hietanen S
Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
[TBL] [Abstract][Full Text] [Related]
26. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
Huang F; Goyal N; Sullivan K; Hanamshet K; Patel M; Mazina OM; Wang CX; An WF; Spoonamore J; Metkar S; Emmitte KA; Cocklin S; Skorski T; Mazin AV
Nucleic Acids Res; 2016 May; 44(9):4189-99. PubMed ID: 26873923
[TBL] [Abstract][Full Text] [Related]
27. The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.
Wang Y; Wang Z; Qi Z; Yin S; Zhang N; Liu Y; Liu M; Meng J; Zang R; Zhang Z; Yang G
Mol Cancer; 2014 Apr; 13():94. PubMed ID: 24775809
[TBL] [Abstract][Full Text] [Related]
28. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.
Samouëlian V; Maugard CM; Jolicoeur M; Bertrand R; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
Cancer Chemother Pharmacol; 2004 Dec; 54(6):497-504. PubMed ID: 15258697
[TBL] [Abstract][Full Text] [Related]
29. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
[TBL] [Abstract][Full Text] [Related]
30. How do real tumors become resistant to cisplatin?
Borst P; Rottenberg S; Jonkers J
Cell Cycle; 2008 May; 7(10):1353-9. PubMed ID: 18418074
[TBL] [Abstract][Full Text] [Related]
31. Molecular Docking of Bioactive Compounds Against BRCA and COX Proteins.
Prog Drug Res; 2016; 71():181-3. PubMed ID: 26939289
[TBL] [Abstract][Full Text] [Related]
32. Drug resistance in the mouse cancer clinic.
Rottenberg S; Borst P
Drug Resist Updat; 2012; 15(1-2):81-9. PubMed ID: 22335919
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.
Stordal B; Davey R
Curr Cancer Drug Targets; 2009 May; 9(3):354-65. PubMed ID: 19442054
[TBL] [Abstract][Full Text] [Related]
34. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.
Guillemette S; Serra RW; Peng M; Hayes JA; Konstantinopoulos PA; Green MR; Cantor SB
Genes Dev; 2015 Mar; 29(5):489-94. PubMed ID: 25737278
[TBL] [Abstract][Full Text] [Related]
35. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
[TBL] [Abstract][Full Text] [Related]
36. Strategies and validation for siRNA-based therapeutics for the reversal of multi-drug resistance in cancer.
Fatemian T; Othman I; Chowdhury EH
Drug Discov Today; 2014 Jan; 19(1):71-8. PubMed ID: 23974068
[TBL] [Abstract][Full Text] [Related]
37. A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.
Higgins GS; Prevo R; Lee YF; Helleday T; Muschel RJ; Taylor S; Yoshimura M; Hickson ID; Bernhard EJ; McKenna WG
Cancer Res; 2010 Apr; 70(7):2984-93. PubMed ID: 20233878
[TBL] [Abstract][Full Text] [Related]
38. Researchers Find New Chemoresistance Mechanism in BRCA-Deficient Tumors.
Balakrishnan VS
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27920054
[No Abstract] [Full Text] [Related]
39. BRCA-deficient animal models and cisplatin resistance.
Muggia F
Ann Oncol; 2009 May; 20(5):962. PubMed ID: 19403936
[No Abstract] [Full Text] [Related]
40. A comprehensive survey of the mutagenic impact of common cancer cytotoxics.
Szikriszt B; Póti Á; Pipek O; Krzystanek M; Kanu N; Molnár J; Ribli D; Szeltner Z; Tusnády GE; Csabai I; Szallasi Z; Swanton C; Szüts D
Genome Biol; 2016 May; 17():99. PubMed ID: 27161042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
